Diabetes drug classes linked to Parkinson’s risk in a sleep disorder
Glucagon-like peptide-1 receptor agonists were linked to lower Parkinson’s risk than dipeptidyl peptidase-4 inhibitors, with a hazard ratio, measuring relative risk, of…Glucagon-like peptide-1 receptor agonists were linked to lower Parkinson’s risk than dipeptidyl peptidase-4 inhibitors, with a hazard ratio, measuring relative risk, of 0.02.